Q-omics provides the consensus-scored DEFB109F profile across patient tissues and cancer cell-line models. DEFB109F expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, DEFB109F is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, DEFB109F RNA expression shows 15,496 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KICH, and UVM as cancer lineages where DEFB109F shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB109F — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB109F survival associations across molecular data types. DEFB109F RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB109F RNA expression–survival associations across cancer types. High DEFB109F expression shows unfavorable associations in COAD, MESO, READ and STAD, but favorable associations in BRCA and SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BRCA as the clearest survival context for DEFB109F RNA expression.
This table summarizes DEFB109F tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for DEFB109F. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB109F shows lower tumor expression in KICH, KIRC, BRCA, LUAD, READ and UCEC. The KICH box plot shows higher DEFB109F RNA expression in normal versus tumor tissue (log2 FC = −0.659, t-test p < 0.001).
This table shows molecular features associated with DEFB109F in patient tissues and cancer cell lines. In patient samples, DEFB109F shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
